1 **Prognostic significance of protein-coding and long non-coding RNA expression profile in T-cell**

2 **acute lymphoblastic leukemia**

3 Deepak Verma¹, Shruti Kapoor⁷, Disha Sharma⁷, Jay Singh¹, Gunjan Sharma⁶, Sarita Kumari¹, 4 Mohit Arora⁶, Sameer Bakhshi², Rachna Seth³, Baibaswata Nayak⁵, Atul Sharma², Raja 5 Pramanik², Jayanth Kumar Palanichamy⁶, Sridhar Sivasubbu⁷, Vinod Scaria⁷, Rajive Kumar⁸, 6 Anita Chopra^{1*} 7 8 9 ¹Laboratory Oncology, Dr BRAIRCH, All India Institute of Medical Science, New Delhi, India ² Medical Oncology, Dr BRAIRCH, All India Institute of Medical Science, New Delhi, India ³ Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India ⁴ Department of Biostatistic, All India Institute of Medical Sciences, New Delhi, India ⁵ 13 ⁵ Department of Gastroenterology, All India Institute of Medical Science, New Delhi, India ⁶ Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India 15 ⁷ CSIR- Institute of Genomics and Integrative Biology, New Delhi, India 16 Mahavir Cancer Institute & Research Centre, Patna, India 17 18 19 *Corresponding Author: Anita Chopra, Laboratory Oncology, Dr BRAIRCH, All India Institute 20 of Medical Science, New Delhi, India 21 22 Email: dranitachopra@aiims.edu , chopraanita2005@gmail.com $\frac{23}{24}$ Abstract

25 T-acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy associated with 26 poor outcome. To unravel gene-expression profile of immunophenotypic subtypes of T-ALL, we did 27 transcriptome analysis in 35 cases. We also analyzed the prognostic relevance of 23 targets: protein-28 coding genes, histone modifiers and long non-coding RNA (lncRNA) expression profile, identified on 29 RNA sequencing, on an independent cohort of 99 T-ALL cases. We found high expression of *MEF2C* to 30 be associated with prednisolone resistance (*p=*0.048) and CD34 expression (*p*=0.012). *BAALC* expression 31 was associated with expression of CD34 (*p=*0.032) and myeloid markers (*p=*0.021). *XIST* and *KDM6a* 32 expression levels were higher in females (*p=*0.047 and 0.011, respectively). Post-induction minimal 33 residual disease (MRD) positivity was associated with high lncRNA PCAT18 (*p=*0.04), *HHEX* (*p=*0.027) 34 and *MEF2C* (*p=*0.007). Early thymic precursor (ETP-ALL) immunophenotype was associated with high 35 expression of *MEF2C* (*p=*0.003), *BAALC* (*p=*0.003), *LYL1* (*p=*0.01), *LYN* (*p=*0.01), *XIST* (*p=*0.02) and

1 low levels of *ST20* (*p=*0.007) and *EML4* (p=0.03). On survival analysis, *MEF2C* high expression 2 emerged as significant predictor of 3-year event free survival (EFS) (low 71.78+6.58% vs high 3 36.57+10.74%, HR 3.5, *p=*0.0003) and overall survival (OS) (low 94.77+2.96% vs high 78.75+8.45%, 4 HR 4.88, *p=*0.016) in our patients. LncRNA MALAT1 low expression also emerged as predictor inferior 5 OS (low 76.02+10.48 vs high 94.11+3.31, HR 0.22, *p=*0.027).

6 **Keywords**

7 RNA-Sequencing, T-cell acute lymphoblastic Leukemia, Early thymic precursor, LncRNA, Gene 8 expression profile.

9 **Introduction**

10 T-lineage acute lymphoblastic leukemia (T-ALL) accounts for ~25% of adults and 10%–15% of pediatric 11 . ALL cases¹. In the past several years immunological, cytogenetic and genomic approaches have been 12 extensively utilized for a better understanding of the genomic organization of functional elements and 13 their alterations in leukemia. This, combined with techniques of cell biology, applied to T-ALL has led to 14 major advances in our understanding of this disease and has allowed the development of novel therapeutic 15 approaches.

16 The malignant transformation that culminates in T-ALL is a multi-step process, in which both genetic and

17 epigenetic alterations of key cellular pathways coordinate to produce the T-ALL phenotype (Peirs et al.,

18 2015; Girardi et al., 2017). T-ALL pathogenesis is characterized by an abnormality with highly variable

19 gene expression profiles. The genetic alterations and transcriptomic signatures are often used for

20 classification of T-ALL patients into molecular subtypes exhibiting distinct clinical outcomes which are

21 partly determined by their underlying oncogenic signalling pathways, such as *IL7R/JAK/STAT*,

22 *PI3K/AKT*⁵⁻⁷ and *RAS/MEK/ERK*⁸ signaling. Aberrant expression of a diverse group of transcription

- 23 factors such as *LYL1, LMO1, LMO2, TAL1, TLX1, TLX3, HOXA, NKX2.1, NKX2.2, NKX2.5, MYC, MYB*
- 24 and *SPI1* has been reported in distinct T-ALL subtypes^{3,4}. Some of the less understood facets in T-ALL

1 include epigenetic deregulation, ribosomal dysfunction, and altered expression of oncogenic miRNAs and 2 long non-coding RNA. Apart from the genetic alterations, epigenetic alterations such as DNA 3 methylation, histone modifications, chromosomal remodelling are chromosomal topology have also been 4 shown to be involved in T-ALL pathogenesis and modulation of clinical response (Van der Meulen et al., 5 2014; Kloetgen et al., 2020).

6 More recently, a greater understanding of molecular pathophysiology and immunophenotyping methods

7 led to the refinement of classification of T-ALL but the clinical relevance of these subtypes remains

8 controversial^{1,9-11}. The only subtype of T-ALL which has got a place in the 2016 revision of WHO, is

9 early thymic precursor ALL $(ETP-ALL)^{11,12}$. In this study, we analyzed the relevance of T-ALL

10 immunophenotyping and the expression pattern of protein-coding genes, epigenetic modifiers and long

11 non-coding RNAs in T-ALL classification and also determined their association with patient prognosis.

12 **Materials and Methods**

13 A total of 134 T-ALL cases, newly diagnosed based on morphology, cytochemistry and

14 immunophenotyping, were enrolled in this study. These cases were immunophenotypically classified into

15 immature (pro T- and pre T-), cortical and mature T-ALL based on the EGIL criteria¹³. ETP-ALL was

16 recognized based on the previously defined criteria¹². The Patients were divided into 2 cohorts: discovery

17 (n=35) and validation cohort (n=99). Total RNA sequencing was done in the discovery cohort. The

18 clinical and prognostic relevance of transcriptomic features identified in the discovery cohort were tested

19 in the validation cohort. All patients or guardians gave informed consent for blood/bone marrow

20 collection and biological analyses, in agreement with the Declaration of Helsinki. The study was

21 approved by the Institutional Ethical Committee, All India Institute of Medical Sciences, New Delhi,

22 India. Transcriptome data of pooled RNA extracted from 5 normal human thymus samples were used as a

23 non-cancer control (kind courtesy Dr Jan Cools, Belgium).

24 *Discovery cohort*

4

5 **RNA sequencing and analysis of the discovery cohort**

6 RNA was extracted from freshly isolated patient blood samples by the TRIzol method (Thermo Fisher 7 Scientific, Massachusetts, USA). Transcriptome data of pooled total RNAs from 5 normal human thymus 8 was used as a control (kindly gifted by Dr Jan Cools, Belgium) for analysis of epigenetic modifiers and 9 miRNA. Paired-end whole transcriptome sequencing was performed on the Illumina HiSeq2000 platform 10 using Truseq RNA sample preparation kit (Illumina, San Diego, California, U.S.). Sequence reads were 11 processed to identify the expression profile of protein-coding and non-coding RNAs by supervised and 12 unsupervised approaches **(supplementary methods).** To investigate the role of histone modifiers in T-13 ALL development, transcript abundance of epigenetic modifiers was measured across mature, cortical, 14 and immature subtypes of T-ALL (supplementary methods). To know the novel lncRNA transcript, a 15 computational pipeline combining Open Reading Frame (ORF) prediction coupled with coding potential 16 calculator (CPC algorithm) to annotate the *protein-coding* potential of transcripts, was used 17 (supplementary methods). Biomart was utilized to identify the annotated miRNA and transcripts. 18 Transcripts with ≥ 2-FC were selected as differentially expressed putative coding and non-coding 19 transcripts in the given subgroup and heatmap were plotted using MeV. Gene Ontology enrichment and 20 KEGG pathway analyses were used to explore the potential biological processes, cellular components, 21 and molecular functions of differentially expressed genes (DEG). Gene functional analysis was done on 22 DAVID 6.8 database^{14,15}. To predict the functions of highly overexpressed validated genes for the protein-23 coding genes, histone modifiers, lncRNA in all three subgroups of T-ALL, a correlation network analysis 24 was performed using the Rcorr package in R based on Spearman correlation and visualized using 25 . Cytoscape¹⁶. Detailed methods are described in the supplementary methods.

23 **Statistical analyses**

1 Fisher's exact test for categorical data and the nonparametric Mann-Whitney U for continuous variables 2 were used to compare baseline clinical variables across groups in the validation cohort. A P-value <0.05 3 (two-sided) was considered significant. Event-free survival (EFS) was defined as the time from diagnosis 4 to the date of the last follow-up in complete remission or the first event (i.e., induction failure, relapse, 5 secondary neoplasm, or death from any cause). Failure to achieve remission due to non-response was 6 considered an event at time zero. Survival was defined as the time from diagnosis to death or the last 7 follow-up. Patients lost to follow-up were censored at the last contact. The last follow up was carried out 8 on April 2020. The Kaplan-Meier method was used to estimate survival rates, with the differences 9 compared using a two-sided log-rank test. Univariate and multivariate Cox proportional hazard models 10 were constructed for EFS and OS. Covariates included sex, WBC (<50X10⁹/L, \geq 50X10⁹/L), age (<12 11 years vs. >12 years), gene expression, immunophenotype and response to prednisolone treatment and 12 presence of minimal residual disease after the end of induction chemotherapy. Patients with high and low 13 expression were delineated using maximally selected rank statistics as implemented in the maxstat R 14 package (http://cran.r-project.org/web/packages/maxstat/ index.html) for each target (*BAALC, HHEX,* 15 *MEF2C, FAT1, LYL1, LMO2, LYN, TAL1, DOT1L, XIST, PCAT18, PCAT14,* LINC00202, LINC00461, 16 LINC00648*, MEF2C-AS1, ST20, RAG1, EP300, EML4, EZH2, MALAT1* and *KDM6A)*. Statistical 17 analyzed were performed using the SPSS statistical software package (version 20.0), STATA software 18 (version 11) and R statistical software (version). 19 **Data Availability** 20 The RNA-Seq raw data that support the findings of this study are available from the corresponding author 21 upon reasonable request. 22 23 **RESULTS** 24 **A. Discovery cohort**

25 **Distinct profiling of differentially expressed genes expression among T-ALL immunophenotype**

25 that these GEPs could be broadly separated in 3 major clusters (figure 2b), in which **Cluster 1**, **Cluster 2**

1 integral component of the membrane and secretory granules. A complete list of biological processes 2 and cell components are mentioned in figure 4a,b. We further tried to disintegrate the molecular pathways 3 by KEGG in which the immunophenotype associated DEG could be involved. This analysis demonstrated 4 enrichment of cellular pathways such as hematopoietic cell lineage, allograft rejection, transcriptional 5 dysregulation in cancer, toll-like receptor signaling pathway, graft-versus-host disease, cytokine-cytokine 6 receptor interaction, cell adhesion molecules (CAMs). Detailed pathways information showed in figure 7 4c. 8 **Co-expression network analysis** 9 Co-expression networks were constructed for differentially expressed genes between the immature, 10 cortical and mature subgroups (with correlation score≥0.9). The genes included in the analysis 11 were highly expressed in our RNA seq data of T-ALL patients. **Table 1** shows the relation among 12 the *protein-coding* and *non-coding genes.* Coexpression networks of *BAALC*, *MEF2C*, lncRNA and 13 epigenetic modifiers are described in supplimentry figures 1a-b, 2a-b respectively. 14 **Long non-coding RNA (lncRNA)** 15 **RNA-seq analysis post annotation and differential expression analysis resulted in 2,243 lncRNAs** 16 **which were expressed in the T-ALL samples. A total of** 223 lncRNAs were filtered based on the 17 criteria of >2FPKM scores. We observed differentially enriched lncRNA in the subgroup of T-ALL such 18 as *HOTTIP* in immature T-ALL; LINC01221, LINC00202, LINC00461, LINC00648 in cortical T-ALL 19 and *MALAT1, ST20 and TRBV11* in mature T-ALL, to be overexpressed. Interestingly, these lncRNAs 20 have not been earlier reported in T-ALL (figure 3a). X-inactive specific transcript (*XIST)*, which is known 21 to have a role in multiple cancers, was expressed in both immature and cortical $T-ALL^{19}$. LUNAR1, 22 which is known to be a specific *NOTCH1*-regulated lncRNA, was expressed in cortical and mature T- 23 \blacksquare ALL²⁰. The co-expression network for HOTTIP, which was highly expressed in immature T-ALL, was 24 constructed and observed to exhibit a strong positive correlation with important transcription factors, 25 having a role in/ previously reported to be involved in T-ALL pathogenesis. (supplimentry figure 2a). In

1 comparison with normal thymus transcriptome, we found lncRNAs, PCAT14 and PCAT18, to be

2 significantly overexpressed in T-ALL cases.

3 In addition to the annotated lncRNA though less explored in T-ALL, we also identified 1,290 4 novel putative *non-coding* transcripts or lncRNA in our data. All transcripts which overlapped 5 coding potential were removed from the analysis as these could potentially contribute to false-6 positive annotations.

- 7
- 8 *Validation cohort*

9 **Correlation between gene expression, response to chemotherapy and outcome**

10 The mRNA expression levels of differentially expressed 23 targets selected from discovery cohort based

11 on their variable expression pattern in distinct immunophenotype, including protein-coding genes,

12 epigenetic modifiers and lncRNA transcripts: *BAALC, HHEX, MEF2C, FAT1, LYL1, LMO2, LYN, TAL1,*

13 *DOT1L, XIST, PCAT18, PCAT14, LNC202, LNC461, LNC648, MEF2C-AS1, ST20, RAG, EP300, EML4,*

14 *EZH2, MALAT1* and *KDM6A*. These genes were further validated in the validation cohort to assess their

15 clinical significance. Interestingly inconsistency to the results obtained in RNA seq analysis we observed

16 the similar pattern of overexpression in distinct immunophenotypes in the validation cohort. High

17 expression of *BAALC* (*p=*0.001), *MEF2C* (*p=*0.002), *LYL1* (0.018), *HHEX* (*p=*0.007) and low expression

18 of *EZH2* (*p=*0.005) were found significantly associated with the immature T-ALL immunophenotype.

19 *RAG1* and FAT1 expression were higher in cortical T-ALL (*p=*0.004 and 0.033, respectively). *DOT1L*

20 expression was higher in mature T-ALL (*p=*0.025). ETP-ALL immunophenotype was associated with

21 high levels of *BAALC* (*p=*0.003), *MEF2C* (*p=*0.003), *LYL1* (*p=*0.01), *LYN* (*p=*0.01), *XIST* (*p=*0.02) and

22 lower levels of *ST20* (*p=*0.007) and *EML4* (*p=*0.03). We also observed an association between CD34

23 positivity on immunophenotyping with expression levels of *BAALC* (*p=*0.032) and *MEF2C* (*p=*0.012).

24 Myeloid markers (CD13/CD33) expression on immunophenotyping was associated with high *BAALC*

25 (*p=*0.021) and low *ST20* (*p=*0.007) and low *KDM6A* (*p=*0.026). We did not find any significant

8 **Association of protein and non-coding RNAs levels with patient variables**

9 On analysis of the potential association of patient's characteristics with expression levels of protein and

10 non-coding RNAs, we found an association between *RAG1* expression and age of the patients. *RAG1*

11 expression was higher in patients <12 years as compared to age >12 years (*p=*0.034). *XIST* and *KDM6A*

12 expression were higher in females (*p=*0.047; 0.011, respectively). We did not find any association

13 between WBC count at diagnosis and all parameters tested. Patients with low *XIST* expression and high

14 *TAL1* more frequently had NCI high risk (*p=*0.01). Prednisolone resistance was associated with high

15 *MEF2C* expression ($p=0.048$). Post-induction MRD positivity ($\geq 0.01\%$) was associated with high

16 expression of PCAT18 (*p=*0.04), *HHEX* (*p=*0.027) and *MEF2C* (*p=*0.007). (Table 2)

17 **Survival analysis**

- 18 Complete remission was achieved in 78 (87.64%) patients with induction chemotherapy. Median follow
- 19 up was 22 months. The 3 year EFS (+SE) and OS (+SE) was 62.23+5.86% and 90.40+3.24%,
- 20 respectively. On univariate analysis, we observed high *MEF2C* expression (low 71.78+6.58% vs high
- 21 36.57+10.74, HR 3.5, 95% confidence interval 1.67-7.3, *p=*0.0003), high *LYL1* expression (low
- 22 63.14+6.65% vs 26.67+15.9%, HR 2.69, 95% confidence interval 1.08-6.69, *p=*0.029), low *ST20* (low
- 23 43.21+13.56 vs high 61.02+7.26, HR 0.45, 95% confidence interval 0.19-1.03, *p=*0.049), low *RAG1*
- 24 expression (low 41.67+12.9 vs high 61.24+7.49, HR 0.45, 95% confidence interval 0.20-0.99, *p=*0.037),

14 **Discussion**

15 With the advancement of molecular techniques, T-ALL has been extensively molecularly characterized.

16 Although genetically heterogeneous, T-ALL can be categorized into various subtypes based on gene

17 expression profiles. Although, unlike B-ALL, molecular features in T-ALL have not been utilized for risk

18 stratification in clinical practice. Furthermore, only a limited number of studies have recently reported

19 prognostic relevance of lncRNAs and epigenetic modifiers in T-ALL. In this study on 134 T-ALL cases,

20 we performed high throughput RNA sequencing in the discovery cohort (n=35) and identified several

21 protein-coding and non-coding transcripts which exhibit differential expression among

22 immunophenotypic subtypes of T-ALL viz. immature, cortical and mature T-ALL. Furthermore, we also

23 validated the expression of 23 identified targets in T-ALL patients and assessed their clinical significance.

24 The key genes which served as transcription factors in early hematopoiesis like *MEF2C, LYL1, LMO2,*

25 *HHEX, RUNX2, HOXA10, HOXA9, RUNX1T1* and *ZBTB16* were upregulated in immature T-ALL.

17 resistance to chemotherapy^{29,32-35}. Baldus et al, 2007³³, reported that high *BAALC* expression was

18 associated with poor long-term survival in T-ALL. On contrary to their observation, we did not find any

19 significant association between *BAALC* expression and prednisolone sensitivity. Like previous studies, we

found *BAALC* overexpression to be associated with the expression of CD34 and myeloid markers^{29,31}.

21 However, we did not find any association between *BAALC* expression and patient outcome. We also

22 found overexpression of *ZBTB16 (PLZF)* in our patients of immature T-ALL, although not stressed in

23 previous western studies, was a notable finding in a recently reported study^{21,36}. *ZBTB16* (or

24 promyelocytic leukemia zinc finger, PLZF) contains one BTB domain and nine zinc finger motifs. Its

25 overexpression was shown in this study to be a result of *ZBTB16-ABL1* translocation and occurred in

1 Mature T-ALL is a rare subgroup and immunophenotypically diagnosed by CD1a- and sCD3+.

- 2 Molecularly *TAL1* has been identified as a driver gene for late cortical T-ALL¹. We observed *TAL1* be
- 3 overexpressed in both mature and cortical T-ALL in our study. Among the protein-coding genes, *APC2,*
- 4 *BCL3, CCR4, ST20, EML4* and *NCOR2* were some of the key upregulated genes.

5 Aberrant histone modifications are the hallmark for cancer and are associated with dysregulated 6 expression of histone modifiers. Therefore, we also studied their expression pattern of epigenetic 7 modifiers to identify a set of histones modifying enzymes to be upregulated or downregulated specifically 8 to the subtype of T-ALL. *EZH2,* a member of the polycomb repressor complex, which is known to be 9 under-expressed in our immature T-ALL cases. This may be related to their previously reported mutations 10 in immature T-ALL³⁹. Danis et al⁴⁰, mechanistically linked *EZH2* inactivation to stem-cell-associated 11 transcriptional programs and increased growth/survival signaling, features that convey an adverse 12 prognosis in patients. However, we did not observe the association between *EZH2* expression and clinical 13 outcome. Loss-of-function mutations and deletions in *SETD2* have been shown to lead to chemotherapy 14 tolerance and clonal survival by cell cycle arrest followed by apoptosis. Further, overexpression of 15 *SETD2* has been demonstrated to confer chemotherapy resistance in a variety of cancers including 16 leukemias^{39,41-43}. We also observed overexpression of *SETD2* in T-ALL as compared to the normal 17 thymus. Therefore, the potential role of SETD2 overexpression in therapeutic resistance in T-ALL 18 requires further investigation. In pediatric cases, higher expression of *HDAC7* and *HDAC9* in ALL is 19 associated with poor prognosis. In our study, we observed overexpression of *HDAC9* in our immature and 20 cortical cases. *CREBBP, EP300, ASH1L, ATM, PKN1, KDM2B, KDM4B* and *DOT1L* showed 21 significant differential expression in mature T-ALL. In the context of transcription coactivation, *EP300* and *CREBBP* have lysine acetyltransferase activity⁴⁴⁻⁴⁷. Targeted histone lysine 23 acetylation of *EP300* and *CREBBP* can influence chromatin conformation⁴⁶, and concomitant binding of *EP300* and acetylation of H3K27 is a hallmark of promoter or enhancer activation⁴⁸.

1 We also found low expression of *ST20* (figure 5c)and *EML4*(figure 5e) to be associated with 2 poor EFS. This has not been reported before.

3 DOT1-like (*DOT1L*) histone lysine methyltransferase methylates H3K79 and plays an important 4 role in embryogenesis and hematopoiesis (Ref). Its aberrant activation is associated with acute 5 leukemias^{49,50}, but Its function is unknown in T-ALL. *DOT1L* catalytic activity depends on the 6 mono-ubiquitination of lysine120 in histone H2B (H2BK120Ub), which provides crosstalk 7 between various histone post-translational modifications⁵¹. Recent studies suggested the role of 8 *DOT1L* in H3K79 methylation and mono-ubiquitination of lysine (H2BK120Ub) that may pave 9 the way for the development of novel *DOT1L*-driven anti-leukemia therapies.⁵²⁻⁵⁶ *DOT1L* was 10 overexpressed in our mature T-ALL patients and it may be worth investigating if they could be 11 subjects for *DOT1L*-driven anti-leukemia therapy. We found *DOT1L* low expression to be 12 associated with poor OS. This has never been reported before. 13 Apart from proteins, non-coding transcript's/ RNA repertoire forms another layer of regulatory paradigm 14 in normal cell hemostasis. Using RNA-seq, we identified the differentially expressed non-coding RNAs 15 especially lncRNAs which have been very well documented earlier for their role in cancers. Our analysis 16 revealed 223 lncRNAs, showing differential expression among various T-ALL subtypes. *NOTCH1*- 17 regulated lncRNA, LUNAR1, was overexpressed in cortical and mature T-ALL 20 . This may be related to 18 a higher incidence of activating *NOTCH1*1 mutations in this T-ALL subtypes¹. HOTTIP and *MEF2C*-19 AS1 were overexpressed in immature; LINC00202, LINC0648, LINC00461 in cortical T-ALL and 20 MALAT1 in mature T-ALL. These have not been reported in T-ALL before in the English literature. We 21 did not find any significant association between their expression with immunophenotypic subtypes. 22 HOTTIP has been reported to be aberrantly activated in AML. It promotes hematopoietic stem cell 23 renewal leading to AML-like disease in mice.⁵⁷ This may explain its overexpression in immature T-ALL 24 which has myeloid potential in our study. MALAT1 is known to be involved in a plethora of

17

25 Leukemia. Cold Spring Harb Perspect Med. 2020 Mar 2;10(3). pii:a035246.

1 **Legends to Tables and figures**

- 2 **Table 1:** Co-expression network analysis of few selected protein-coding and non-coding genes
- 3 **Table 2:** Association of expression of various protein and non-protein coding RNAs with
- 4 patients' characteristics
- 5 **Table 3:** Association of patients' characteristics with EFS and OS
- 6 **Table 4: (a)** Multivariate Cox regression analysis for EFS **(b)** Multivariate Cox regression
- 7 analysis of OS
- 8 **Figure 1**: Workflow for identification and validation of molecular markers in T-ALL patients.
- 9 **Figure 2**: **(a)** Radar graph of Differentially expressed genes among T-ALL subgroups: immature
- 10 (Blue), cortical (Green), mature (Gray). each circle represents the fold change for the
- 11 differentially expressed genes. **(b)** PCA analysis of Gene expression: Figure depicts the
- 12 clustering of samples in 3 major clusters according to their normalized FPKM count. Cluster 1
- 13 comprises of 9, Cluster 2 comprises 5 and Cluster 3 comprises 19 T-ALL samples.
- 14 **Figure 3: (a)** Hierarchical clustering of differential expressed lncRNA among three T-ALL
- 15 subgroups. **(b)** Hierarchical clustering differentially expressed epigenetic modifiers in T-ALL.;
- 16 Each raw represents gene symbol. The "heat map" indicates high (red) or low (green) level of
- 17 expression according to the scale shown.
- 18 **Figure 4:** Enriched gene ontology functions of deferentially expressed genes, DAVID results
- 19 the number of involved genes from differentially expressed genes in T-ALL for biological
- 20 process **(a)**, cellular components **(b)** and KEGG pathways**(c).** (p<0.005). Complete list of genes
- 21 involved in the biological process and cellular component of are shown in Supplementary
- 22 **Figure 5.** Kaplan Meier analysis for event free survival for expression of **a.** *MEF2C*, **b.** *LYL1*, **c.**
- 23 *ST20*, **d.** *RAG1*, **e.** *EML4* and **f.** *KDM6A* genes.

- 1 **Figure 6.** Kaplan Meier analysis for overall survival for expression of **a.** *MEF2C*, **b.** *DOT1L*, **c.**
- 2 *RAG1*, **d.** *MALAT1.*

Validation of RNAseq data on discovery cohort

Biological F rocess: T-ALL

Cellular component: T-ALL

b

C

KEGG Pathways: T-ALL

Table 1: Co-expression network analysis of few selected protein-coding and non-coding genes

Table 2: Association of expression of various protein and non-protein coding RNAs with patients' characteristics

Table 3: Association of patients' characteristics with EFS and OS

Table 4a: Multivariate Cox regression analysis for EFS